



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)
(Stock Code 股份代號: 1541)

20 February 2024

Dear registered shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”) is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “**Corporate Communications**”), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.immuneonco.com and the HKEXnews website at www.hkexnews.hk in place of printed copies (the “**Website Version**”). A notice of publication of the Website Version of Corporate Communications, in both English and Chinese, will be sent by the Company to its shareholders by email or by post (only if the Company does not possess the functional email address of the shareholder) on the publication date of the Corporate Communications.

To ensure timely receipt of all future Corporate Communications, the Company recommends you provide your email address by scanning the QR code printed on the reply form enclosed (the “**Reply Form**”). Alternatively, you may sign and return the Reply Form to the Company at Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai PRC.

If the Company does not receive your functional email address in your reply, until such time that the functional email address is provided to the Company, you will (i) be unable to receive any notifications regarding the publication of Corporate Communications by email; and (ii) need to proactively check the Company’s website and the HKEXnews website to keep up with the publication of Corporate Communications.

If you want to receive the Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the Company, Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai PRC or send an email to ir@immuneonco.com specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the Company at 86-021-38016387 during business hours from 9:00 a.m. to 5:30 p.m. (Hong Kong time), Mondays to Fridays, excluding public holidays in Hong Kong and Mainland China.

Yours faithfully,
By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Tian Wenzhi
Chairman

各位登記股東：

以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則（「**上市規則**」）第 2.07 條，宜明昂科生物醫藥技術（上海）股份有限公司（「**公司**」）謹此通知 閣下，公司已採用以電子方式發布公司通訊（「**公司通訊**」）之安排，該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及其中期報告摘要（如適用）；(c) 會議通知；(d) 上市文件；(e) 通函和 (f) 委任表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 www.immuneonco.com 和披露易網站 www.hkexnews.hk 上提供，以代替印刷本（「**網站版本**」）。本公司將於公司通訊刊發日期通過電子郵件方式或郵寄方式（僅在本公司沒有獲取股東有效的電子郵箱地址時）向股東發送公司通訊網站版本的登載通知，該通知將同時提供英文和中文版本。

為了確保及時收到所有未來的公司通訊，公司建議閣下透過掃描所附回條上列印的二維碼來提供閣下的電子郵件地址。或者，閣下可以簽署回條並交回公司，地址為上海浦東新區張衡路 1000 弄 15 號樓。

如果公司沒有從閣下回復收到閣下的有效電子郵件地址，直至公司收到閣下有效的電子郵件地址前，閣下將(i)無法收到任何有關發布公司通訊的通知；及(ii)需要主動查看公司網站和披露易網站以留意公司通訊的發佈。

若 閣下希望收取公司通訊之印刷版，請填妥本函背頁之回條並交回公司，地址為上海浦東新區張衡路 1000 弄 15 號樓或發送電子郵件至 ir@immuneonco.com，並註明閣下的姓名、地址以及收取公司通訊印刷版的要求。請注意，收取日後公司通訊印刷版之指示由收悉閣下指示當日起計一年內有效，此後將過期。

如 閣下對本函件有任何疑問，請於辦公時間星期一至五（香港及中國大陸公眾假期除外）上午 9 時正至下午 5：30 時（香港時間）其間致電公司 86-021-38016387 查詢。

承董事會命
宜明昂科生物醫藥技術（上海）股份有限公司
田文志
董事長
謹啟

2024 年 2 月 20 日

